Immunotherapy in mesothelioma patients.

Recruiting

Conditions: mesotheliomamesothelioomasbestkankerborstvlieskanker

Registration Number: NL-OMON24867

Lead Sponsor: Erasmus Medical CenterDepartment of Pulmonary MedicineRotterdam

Brief Summary: Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med 2005; 171:1168-77. <br><br> Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006; 27:1086-95.

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 10

Inclusion Criteria

1. Patients with clinically and histological or cytological confirmed newly diagnosed MM, that can be measured in two dimensions by a radiologic imaging study;

2. Patients must be at least 18 years old and must be able to give written informed consent;

Exclusion Criteria

1. Conditions that make the patient unfit for chemotherapy or progressive disease after 4 cycles of chemotherapy;

2. Pleurodesis at the affected side before the pleural fluid is obtained;

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The aim of this new phase I protocol is to study the toxicity and safety of low dose CTX in combination with DC-based immunotherapy in MM patients.

Secondary Outcome Measures

Name	Time	Method
Secondary end-points include the establishment of an immune response against TAA and KLH. Read-out parameters are the side effects, immune responses, anti-tumor response and survival of the combined ¡°CTX and DC-based immunotherapy¡± both in vivo and in vitro.